Members-only Site   |   Print Page   |   Contact Us   |   Sign In   |   Register
News & Press: Breaking News

ACTION ALERT: Ask Your Representatives to Cosponsor HR 2871

Friday, June 23, 2017   (0 Comments)
Posted by: Dagmar Anderson
Share |

Ask Your Representatives to Cosponsor HR 2871 - The Preserving Patient Access to Compounded Medications Act 

The International Academy of Compounding Pharmacists (IACP) Applauds the Leadership of Congressmen Morgan Griffith (VA) and Henry Cuellar (TX) in introducing HR 2871, a bipartisan effort that will preserve patient access to vital compounded medications.

Take Action!

Please Click Here to send a direct communication to your Representative.

It will only take a few minutes with IACP's easy-to-use Voter Voice action alert platform. 

This important bill will help protect access to compounded medications on which your patients rely. It will help clarify the Drug Quality & Security Act (DQSA) in a way that will better align the statute with congressional intent and better balance public safety and patient access. 

Urge your Representatives to Cosponsor this Legislation because it will:

  • Provide the records and registration exemptions provided to pharmacies under the Food Drug and Cosmetic Act (FDCA) when inspected by FDA to compounding pharmacies that are compliant with state and local pharmacy laws and 503A of the FDCA.
  • Allow for "office-use" compounding of medications where authorized by state law.
  • Allow for compounding with dietary supplements that comply with the monograph standards of the US Pharmacopoeia or National Formulary.
  • Prevent FDA regulatory authority over interstate "dispensing" of compounded medications pursuant to prescriptions for identified patients, which is left to state law and state boards of pharmacy.
  • Require FDA to follow formal rulemaking procedures that allow stakeholder input and decrease confusion by providing formal FDA procedure and statements on the record. Currently, FDA is issuing "guidance documents" that FDA is enforcing through Warning Letters without following formal rulemaking procedures.

As such, it's vital that Congress support HR 2871 in order to preserve patient access to compounded medications by directing FDA to act within Congressional intent.

Thank you! Please email IACP with any questions at

Association Management Software Powered by YourMembership  ::  Legal